Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 31 unusual trades. Delving into the details, we found 51% of ...

The mRNA treatment landscape is shaping up to be competitive, but the market is also nascent, with the covid pandemic marking the first commercial product from Moderna, the industry leader.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

This diverse pipeline exemplifies Moderna's road map to extend its mRNA technology into new categories, positioning itself as a more diversified and mature commercial-stage biotech company.

Since reaching a peak last May, Moderna stock has tumbled by about 79%, and investors are starting to wonder if it could be a ...